1. Home
  2. DLHC vs ATYR Comparison

DLHC vs ATYR Comparison

Compare DLHC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLH Holdings Corp.

DLHC

DLH Holdings Corp.

HOLD

Current Price

$5.55

Market Cap

80.6M

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.71

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLHC
ATYR
Founded
1969
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.6M
79.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
DLHC
ATYR
Price
$5.55
$0.71
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$8.75
AVG Volume (30 Days)
29.9K
2.3M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$344,497,000.00
$190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,728.88
P/E Ratio
$62.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$0.64
52 Week High
$8.45
$7.29

Technical Indicators

Market Signals
Indicator
DLHC
ATYR
Relative Strength Index (RSI) 37.83 36.93
Support Level $5.50 $0.70
Resistance Level $5.65 $0.83
Average True Range (ATR) 0.18 0.05
MACD -0.07 0.01
Stochastic Oscillator 6.17 4.95

Price Performance

Historical Comparison
DLHC
ATYR

About DLHC DLH Holdings Corp.

DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: